Compare ALG & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | COAG |
|---|---|---|
| Founded | 1955 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1996 | 2026 |
| Metric | ALG | COAG |
|---|---|---|
| Price | $134.49 | $48.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $199.75 | $62.67 |
| AVG Volume (30 Days) | 137.5K | ★ 423.2K |
| Earning Date | 11-02-2026 | 11-10-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.14 | N/A |
| Revenue | ★ $1,603,715,000.00 | N/A |
| Revenue This Year | $6.09 | N/A |
| Revenue Next Year | $4.44 | N/A |
| P/E Ratio | $28.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $133.32 | $27.38 |
| 52 Week High | $219.88 | $55.42 |
| Indicator | ALG | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 27.68 | 78.49 |
| Support Level | N/A | $42.24 |
| Resistance Level | $171.56 | $51.50 |
| Average True Range (ATR) | 5.88 | 2.72 |
| MACD | -0.69 | 1.60 |
| Stochastic Oscillator | 7.49 | 99.58 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Its products include agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck-mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, snow removal equipment, etc. The company's reportable segments are Vegetation Management, which generates the maximum revenue, and Industrial Equipment. Geographically, the company generates maximum revenue from the United States, followed by Canada, France, the UK, Brazil, the Netherlands, and other regions.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.